Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI
· Real-Time Price · USD
16.11
-0.54 (-3.24%)
At close: May 01, 2025, 3:59 PM
16.06
-0.31%
After-hours: May 01, 2025, 04:05 PM EDT
-3.24% (1D)
| Bid | 15.45 |
| Market Cap | 2.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -422.77M |
| EPS (ttm) | -2.57 |
| PE Ratio (ttm) | -6.27 |
| Forward PE | -6.47 |
| Analyst | Buy |
| Ask | 17 |
| Volume | 848,523 |
| Avg. Volume (20D) | 1,361,827 |
| Open | 16.53 |
| Previous Close | 16.65 |
| Day's Range | 15.73 - 16.62 |
| 52-Week Range | 10.57 - 33.33 |
| Beta | 1.58 |
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2017
Employees 422
Stock Exchange NASDAQ
Ticker Symbol DNLI
Analyst Forecast
According to 16 analyst ratings, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 104.84% from the latest price.
Stock ForecastsNext Earnings Release
Denali Therapeutics Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+11.8%
Denali Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
-8.21%
Denali Therapeutics shares are trading lower after Oppenheimer cut its price target on the stock from $50 to $42.
